<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05793996</url>
  </required_header>
  <id_info>
    <org_study_id>ID-HFpEF</org_study_id>
    <nct_id>NCT05793996</nct_id>
  </id_info>
  <brief_title>The Prevalence of Iron Deficiency and the Effectiveness of Ferinject® in Patients With HFpEF (ID-HFpEF)</brief_title>
  <acronym>ID-HFpEF</acronym>
  <official_title>Study of the Prevalence of Iron Deficiency Among Hospitalized Patients With HFpEF and the Impact of Ferinject® on Indicators of Quality of Life, Functional Status in Patients With Iron Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tomsk National Research Medical Center of the Russian Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tomsk National Research Medical Center of the Russian Academy of Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational cohort randomized controlled study to study the influence of correction of ID&#xD;
      by intravenous injection of ferric carboxymaltose (Ferinject®) on quality of life indicators,&#xD;
      functional status in a cohort of patients with HFpEF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of HFpEF among patients admitted to cardiology hospitals will be studied. The&#xD;
      study will include patients with NYHA II-III who have signed an informed consent that meets&#xD;
      the inclusion/exclusion criteria. The effectiveness of intravenous administration of iron&#xD;
      carboxymaltose (Ferinject ® ) to correct iron deficiency and improve the clinical course of&#xD;
      HFpEF will be evaluated. A group without iron deficiency will be recruited as a control group&#xD;
      (n=30).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2023</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2026</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome (Combined)</measure>
    <time_frame>12 months</time_frame>
    <description>Change of 5 or more points on the Kansas City Cardiomyopathy Questionnaire (KCCQ) (0-100 points)+change in test distance with a 6-minute walk (6MWD - 150 meters or more) by 35 meters or more.&#xD;
An increase in the number of points by 5 on the Kansas City Cardiomyopathy Questionnaire scale, increasing the distance on the 6-minute walk test by 35 meters means a better result.&#xD;
The absence of changes/decrease in the number of points on the Kansas City Cardiomyopathy Questionnaire scale, the absence of changes/decrease in the distance in the 6-minute walking test means the worst result.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changing by 5 or more points on the Kansas City Cardiomyopathy Questionnaire (KCCQ 0-100 points)</measure>
    <time_frame>6 months</time_frame>
    <description>Change of 5 or more points in the Kansas City Cardiomyopathy Questionnaire (KCCQ) (0-100 points).&#xD;
An increase in the number of points by 5 on the Kansas City Cardiomyopathy Questionnaire scale means a better result.&#xD;
The absence of changes/decrease in the number of points on the Kansas City Cardiomyopathy Questionnaire scale means the worst result.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changing in test distance with a 6-minute walk (6MWD 300 meters or more) of 35 meters</measure>
    <time_frame>6 months</time_frame>
    <description>Change in the distance when testing a 6-minute walk by 35 meters or more. An increase the distance on the 6-minute walk test by 35 meters or more means a better result.&#xD;
The absence of changes/decrease in the distance in the 6-minute walking test means the worst result.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changing functional class of chronic heart failure (CHF) by New York Heart Association (NYHA I-IV functional classes)</measure>
    <time_frame>6 months</time_frame>
    <description>Reduction of the functional class of CHF according to New York Heart Association by 1point means a better result.&#xD;
No changes or an increase in the functional class means a worse result.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for heart failure and death from all causes</measure>
    <time_frame>12 months</time_frame>
    <description>The absence of hospitalizations for heart failure and death from all causes means a better result. Hospitalization and death from all causes means the worst result.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changing by 5 or more points according to the Minnesota Heart Failure Quality of Life Questionnaire (MHFLQ) (0-105 points).</measure>
    <time_frame>6 months</time_frame>
    <description>A decrease of 5 or more points on the Minnesota Heart Failure Quality of Life Questionnaire (MHFLQ) means a better result.&#xD;
The absence of changes/increase in the number of points on the Minnesota Heart Failure Quality of Life Questionnaire (MHFLQ) means the worst result.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Heart Failure</condition>
  <condition>Iron Deficiency, Latent</condition>
  <arm_group>
    <arm_group_label>Experimental: 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Ferinject ® (Ferric carboxymaltose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparison Group: 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Diet therapy, without drug therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group: 3</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Without therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferinject</intervention_name>
    <description>The calculation of the dose of iron carboxymaltosate (Ferinject ® preparation) for the purpose of correction of iron will be carried out on the basis of the following step-by-step approach: determination of individual iron needs, calculation and administration of iron dose, assessment of the saturation of the patient's body with iron 6 weeks after infusion.</description>
    <arm_group_label>Experimental: 1</arm_group_label>
    <other_name>Ferric carboxymaltose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet therapy</intervention_name>
    <description>Patients will receive diet therapy to correct latent iron deficiency</description>
    <arm_group_label>Comparison Group: 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent to participate in the study;&#xD;
&#xD;
          -  In New York Heart Association (NYHA) II-III functional class due to stable symptomatic&#xD;
             chronic heart failure (CHF);&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) ≥50%; objective signs of structural and/or&#xD;
             functional disorders of the heart consistent with the presence of LV diastolic&#xD;
             dysfunction/increased LV filling pressure, including elevated levels of natriuretic&#xD;
             peptide;&#xD;
&#xD;
          -  Screening ferritin below 100 µg/L, or below 300 µg/L when transferrin saturation&#xD;
             (TSAT) is below 20%;&#xD;
&#xD;
          -  Screening haemoglobin (Hb) at the time of switching on (in women &gt;120 g/l, in men &gt;130&#xD;
             g/l).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled arterial hypertension;&#xD;
&#xD;
          -  Anemia;&#xD;
&#xD;
          -  Less than 1 year after acute myocardial infarction;&#xD;
&#xD;
          -  Less than 1 year after acute cerebral circulation disorder;&#xD;
&#xD;
          -  Less than 1 year after surgical interventions, including non-cardiac operations and&#xD;
             myocardial revascularization (coronary bypass surgery, coronary artery stenting),&#xD;
             operations for valvular pathology;&#xD;
&#xD;
          -  Chronic alcoholism (including alcoholic heart disease), mental disorders;&#xD;
&#xD;
          -  Severe hepatic (increased transaminase levels above the upper three limits of normal)&#xD;
             and renal insufficiency (glomerular filtration rate less than 15 ml/min/1.73 m2);&#xD;
&#xD;
          -  Known active infection, clinically significant bleeding, active malignancy;&#xD;
&#xD;
          -  Severe autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, etc.);&#xD;
&#xD;
          -  Severe bronchial asthma, COPD in the acute stage;&#xD;
&#xD;
          -  Allergic reactions to medications in the anamnesis, eczema, atopic allergic reaction;&#xD;
&#xD;
          -  Blood transfusions and taking erythropoiesis-stimulating drugs during the previous&#xD;
             three months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alla A. Garganeeva, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olga V. Tukish, Ph.D.</last_name>
    <phone>+79069476343</phone>
    <email>olgatukish@yandex.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences</name>
      <address>
        <city>Tomsk</city>
        <zip>634012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga V. Tukish, Ph.D.</last_name>
      <phone>89069476343</phone>
      <email>olgatukish@yandex.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 1, 2023</study_first_submitted>
  <study_first_submitted_qc>March 30, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2023</study_first_posted>
  <last_update_submitted>April 28, 2023</last_update_submitted>
  <last_update_submitted_qc>April 28, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HFpEF</keyword>
  <keyword>iron deficiency</keyword>
  <keyword>ferric carboxymaltose</keyword>
  <keyword>Ferinject</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

